Q1 EPS Forecast for Merit Medical Systems Cut by Analyst

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Stock analysts at Zacks Research decreased their Q1 2025 earnings per share estimates for shares of Merit Medical Systems in a research note issued to investors on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings per share of $0.76 for the quarter, down from their prior forecast of $0.81. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q2 2025 earnings at $0.96 EPS, Q4 2025 earnings at $1.02 EPS, Q1 2026 earnings at $0.74 EPS, Q2 2026 earnings at $1.08 EPS, Q3 2026 earnings at $1.10 EPS, Q4 2026 earnings at $1.15 EPS and FY2027 earnings at $4.34 EPS.

Several other equities research analysts also recently issued reports on MMSI. Canaccord Genuity Group dropped their price target on shares of Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Barrington Research lowered their target price on Merit Medical Systems from $115.00 to $111.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Piper Sandler reaffirmed an “overweight” rating and issued a $116.00 price objective (up previously from $114.00) on shares of Merit Medical Systems in a report on Wednesday, January 29th. Wells Fargo & Company cut their price objective on shares of Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Finally, Raymond James lifted their price target on Merit Medical Systems from $105.00 to $110.00 and gave the company an “outperform” rating in a research report on Tuesday, December 31st. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Merit Medical Systems presently has a consensus rating of “Moderate Buy” and an average price target of $110.78.

Merit Medical Systems Stock Up 0.4 %

MMSI opened at $101.68 on Thursday. Merit Medical Systems has a 1 year low of $70.70 and a 1 year high of $111.45. The firm has a 50 day moving average price of $103.93 and a 200 day moving average price of $100.75. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. The company has a market cap of $5.98 billion, a PE ratio of 49.84, a price-to-earnings-growth ratio of 2.34 and a beta of 0.91.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in MMSI. Norges Bank bought a new stake in shares of Merit Medical Systems in the fourth quarter valued at approximately $66,638,000. FMR LLC lifted its position in shares of Merit Medical Systems by 70.1% during the 3rd quarter. FMR LLC now owns 1,577,246 shares of the medical instruments supplier’s stock valued at $155,879,000 after acquiring an additional 649,799 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Merit Medical Systems during the 4th quarter worth $48,926,000. Groupama Asset Managment acquired a new stake in shares of Merit Medical Systems during the 4th quarter worth $38,688,000. Finally, Bryn Mawr Capital Management LLC bought a new position in shares of Merit Medical Systems in the fourth quarter worth $36,057,000. Institutional investors and hedge funds own 99.66% of the company’s stock.

Insider Buying and Selling

In other Merit Medical Systems news, CEO Fred P. Lampropoulos sold 31,320 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $103.86, for a total value of $3,252,895.20. Following the transaction, the chief executive officer now directly owns 1,086,028 shares of the company’s stock, valued at $112,794,868.08. This represents a 2.80 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Stephen C. Evans sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $105.31, for a total value of $526,550.00. Following the transaction, the director now owns 4,657 shares in the company, valued at $490,428.67. The trade was a 51.78 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 109,132 shares of company stock worth $11,139,521. Company insiders own 3.70% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.